Red Tree, RA Cap­i­tal lead $108M in­fu­sion in­to Bicara and its bi­func­tion­al I/O drug

Bicara Ther­a­peu­tics, the Bio­con spin­out work­ing on a new kind of im­munother­a­py, has bagged $108 mil­lion to push its lead can­di­date deep­er in­to the clin­ic.

Its top pro­gram, BCA101, hits two fa­mil­iar tar­gets in the can­cer space, EGFR and TGF-β. What Bicara aims to do, though, is cre­ate a bi­func­tion­al an­ti­body that si­mul­ta­ne­ous­ly blocks EGFR and us­es that as a hom­ing mech­a­nism to trap TGF-β, a cy­tokine that pro­motes can­cer growth, at the tu­mor site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER